Regentis Biomaterials Ltd. Financials
RGNT
All currency values in $ millions unless otherwise noted
| Income Statement | DEC 2025 | DEC 2024 | DEC 2023 |
|---|---|---|---|
| Revenues | |||
| Revenue | $0 | $0 | $0 |
| Operating Income | -$9 | $1 | -$2 |
| Non-Operating | |||
| Net Interest Expense | -$0 | -$0 | -$0 |
| Net Income | |||
| Net Income | -$14 | $5 | -$4 |
| Per Share Data | |||
| Revenue Per Share | $0.00 | – | – |
| EPS (Basic) | -$2.64 | – | – |
| EPS (Diluted) | -$2.64 | – | – |
| Shares Outstanding | 5.2M | – | – |
Regentis Biomaterials (RGNT) financials: revenue, profit and margins
Regentis Biomaterials (RGNT) generated about $0.00 in revenue and -$14 million in net income over the trailing twelve months. Figures are from company filings; this is analysis, not investment advice.
Frequently asked
What is Regentis Biomaterials's (RGNT) revenue?+
Regentis Biomaterials generated about $0.00 in revenue over the trailing twelve months. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Is Regentis Biomaterials profitable?+
Regentis Biomaterials reported about -$14 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
Peers
Medical Instruments & Supplies · Pick stocks to compare with RGNT
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing RGNT
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.